Myriad Genetics (MYGN) Expected to Announce Quarterly Earnings on Tuesday

Myriad Genetics (NASDAQ:MYGN) is expected to announce its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $210.35 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Myriad Genetics Stock Down 5.3 %

Shares of NASDAQ MYGN opened at $14.19 on Friday. Myriad Genetics has a 12-month low of $12.04 and a 12-month high of $29.30. The company has a market cap of $1.29 billion, a P/E ratio of -10.92 and a beta of 1.88. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average price of $13.45 and a 200 day moving average price of $19.53.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on MYGN shares. Bank of America lowered their price target on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a report on Friday, December 13th. StockNews.com cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday. Piper Sandler decreased their price objective on shares of Myriad Genetics from $24.00 to $14.00 and set a “neutral” rating for the company in a research report on Thursday, January 30th. Morgan Stanley decreased their price objective on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a research report on Monday, November 18th. Finally, UBS Group began coverage on shares of Myriad Genetics in a research report on Tuesday, December 10th. They issued a “neutral” rating and a $18.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $22.54.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.